<DOC>
	<DOCNO>NCT01033721</DOCNO>
	<brief_summary>Palomid 529 dual TORC1/2 inhibitor PI3K/Akt/mTOR pathway broad activity angiogenesis cellular proliferation . Palomid 529 examined determine safety , tolerability pharmacokinetic profile single ascending dos administer intravitreally subconjunctivally .</brief_summary>
	<brief_title>Phase I Study Palomid 529 Dual TORC1/2 Inhibitor PI3K/Akt/mTOR Pathway Advanced Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Best correct visual acuity study eye 20/100 20/800 ( 53 4 ETDRS letter read ) , good equal 20/200 ( minimum 34 letter read ) fellow eye . Subfoveal choroidal neovascularization ( CNV ) due AMD Total area lesion ( include blood , neovascularization scar/atrophy ) must &lt; 12 DA . Only 1 eye treat study . If eye eligible , investigator select eye active CNV Clear ocular medium adequate pupillary dilatation permit good stereo fundus photography screen Intraocular pressure 21 mm Hg le Retinal thickness ≥ 250 μm OCT , presence intraretinal subretinal fluid Any retinovascular disease retinal degeneration AMD Serous pigment epithelial detachment without presence neovascularization Previous posterior vitrectomy retinal surgery Any periocular infection past 4 week Concomitant therapy antiVEGF therapy , e.g . Avastin , Lucentis Macugen , previous use agent within 60 day screen Concomitant therapy intravenous intravitreous corticosteroid use within 90 day screen Significant medium opacity , include cataract , might interfere visual acuity , assessment toxicity , fundus photography Cataract surgery study eye within 3 month screen Intraocular surgery study eye within 3 month screen Presence ocular infection study eye Presence severe myopia ( 8 diopter great ) study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>